**Core Concept**
Fibrinolytic therapy involves the administration of drugs that break down fibrin clots, which can be life-saving in acute myocardial infarction (AMI) by restoring blood flow to the affected heart muscle. However, this process also increases the risk of bleeding due to the breakdown of existing clots and the inhibition of new clot formation.

**Why the Correct Answer is Right**
The primary concern with fibrinolytic therapy is the risk of hemorrhagic complications, particularly hemorrhagic stroke. This is because the administration of fibrinolytic agents such as streptokinase or alteplase can lead to the breakdown of clots in the cerebral vasculature, resulting in bleeding into the brain. The risk of hemorrhagic stroke is a significant adverse effect of fibrinolytic therapy, and it is a major consideration in the decision to use these drugs in patients with AMI.

**Why Each Wrong Option is Incorrect**
**Option A:** Acute renal failure is not a direct consequence of fibrinolytic therapy, although patients with AMI may have underlying renal dysfunction that can be exacerbated by other factors such as contrast-induced nephropathy.

**Option B:** Development of antiplatelet antibodies is not a known adverse effect of fibrinolytic therapy. While patients receiving fibrinolytic agents may be at risk for bleeding, the development of antiplatelet antibodies is not a relevant concern.

**Option C:** Encephalitis secondary to liver dysfunction is not a direct consequence of fibrinolytic therapy. While liver dysfunction can occur in patients with AMI, it is not a common adverse effect of fibrinolytic therapy.

**Clinical Pearl / High-Yield Fact**
Fibrinolytic therapy should only be used in patients with AMI who have received thrombolytic therapy within the preceding 12-24 hours, as the risk of bleeding is significantly increased in patients who have received fibrinolytic agents within this time frame.

**✓ Correct Answer: D. Hemorrhagic stroke**